Activators of the nuclear hormone receptors PPARα and FXR accelerate the development of the fetal epidermal permeability barrier

Journal of Clinical Investigation

Volumn 100, Issue 3, 1997, Pages 705-712

  Hanley, Karen ^a,b   Jiang, Yan ^a,b   Crumrine, Debra ^a,b   Bass, Nathan M ^a   Appel, Renaissance ^a   Elias, Peter M ^a,b   Williams, Mary L ^a,b   Feingold, Kenneth R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Clofibrate; Farnesol; Juvenile hormone; RXR; Stratum corneum

Indexed keywords

CELL NUCLEUS RECEPTOR; CLOFIBRATE; FARNESOL; JUVENILE HORMONE; PEROXISOME PROLIFERATOR; RECEPTOR PROTEIN; RETINOID; RETINOID X RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EPIDERMIS; FEMALE; FETUS; FETUS DEVELOPMENT; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; RAT; SKIN PERMEABILITY; STRATUM CORNEUM;

EID: 0030835838     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119583     Document Type: Article

References (46)

1. Elias, P.M., and G.K. Menon. 1991. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv. Lipid Res. 24:1-26.
2. Downing, D.T. 1992. Lipid and protein structures in the permeability barrier of mammalian epidermis. J. Lipid Res. 33:301-313.
3. Cartlidge, P.H.T., and N. Rutter. 1992. Skin barrier function. In Fetal and Neonatal Physiology. R.A. Polin and W.W. Fox, editors. W.B. Saunders Co., Philadelphia. 569-585.
4. Harpin, V.A., and N. Rutter. 1983. Barrier properties of newborn infant's skin. J. Pediatr. 102:419-425.
5. Vernon, H.J., A.T. Lane, L.J. Wischerath, J.M. Davis, and M.A. Menegus. 1990. Semi-permeable dressings and transepidermal water loss in premature infants. Pediatrics. 86:357-362.
6. Freinkel, R.F., and T.N. Traczyk. 1985. Lipid composition and hydrolase content of lamellar granules of fetal rat epidermis. J. Invest. Dermatol. 85:295-298.
7. Aszterbaum, M., G.K. Menon, K.R. Feingold, and M.L. Williams. 1992. Ontogeny of the epidermal barrier to water loss in the rat: correlation of function with stratum corneum structure and lipid content. Pediatr. Res. 31:308-317.
8. Hanley, K., U. Rassner, P.M. Elias, M.L. Williams, and K.R. Feingold. 1996. Epidermal barrier ontogenesis: maturation in serum-free media and acceleration by glucocorticoids and thyroid hormone but not selected growth factors. J. Invest. Dermatol. 106:404-411.
9. Aszterbaum, M., K.R. Feingold, G.K. Menon, and M.L. Williams. 1993. Glucocorticoids accelerate fetal maturation of the epidermal permeability barrier in the rat. J. Clin. Invest. 91:2703-2708.
10. Hanley, K., U. Rassner, Y. Jiang, D. Vansomphone, D. Crumrine, L. Komuves, P.M. Elias, K.R. Feingold, and M.L. Williams. 1996. Hormonal basis for the gender difference in epidermal barrier formation in the fetal rat. Acceleration by estrogen and delay by androgen. J. Clin. Invest. 97:2576-2584.
11. Hanley, K., Y. Jiang, W.M. Holleran, P.M. Elias, M.L. Williams, and K.R. Feingold. 1997. Glucosylceramide metabolism is regulated during normal and hormonally-stimulated epidermal barrier development in the rat. J. Lipid Res. 38:576-584.
12. Hanley, K., Y. Jiang, C. Katagiri, K.R. Feingold, and M.L. Williams. 1997. Epidermal steroid sulfatase and cholesterol sulfotransferase are regulated during late gestation in the fetal rat. J. Invest. Dermatol. 108:871-875.
13. Mangelsdorf, D.J., C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumenberg, P. Kastner, M. Mark, P. Chambon, and R.M. Evans. 1995. The nuclear receptor superfamily: the second decade. Cell. 83:835-839.
14. Kastner, P., M. Mark, and P. Chambon. 1995. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell. 83:841-850.
15. Mangelsdorf, D.J., and R.M. Evans. 1995. The RXR heterodimers and orphan receptors. Cell. 83:841-850.
16. Saitou, M., S. Sugal, T. Tanaka, K. Shimouchi, E. Fuchs, S. Narumiya, and A. Kakizuka. 1995. Inhibition of skin development by targeted expression of a dominant-negative retinoic acid receptor. Nature (Lond.). 374:159-162.
17. Imakado, S., J.R. Bickenbach, D.S. Bundman, J.A. Rothnagel, P.S. Attar, X. Wang, V.R. Walczak, S. Wisniewski, J. Pote, J.S. Gordon, et al. 1995. Targeting expression of a dominant-negative retinoic acid receptor mutant in the epidermis of transgenic mice results in loss of barrier function. Genes Dev. 9:317-329.
18. Kang, S., L. Xiao-Yan, and J.J. Voorhees. 1996. Pharmacology and molecular action of retinoids and vitamin D in skin. J. Invest. Dermatol. Symposium Proceedings. 1:15-21.
19. Keller, H., C. Dreyer, J. Medin, A. Mahfoudi, K. Ozato, and W. Wahli. 1993. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA 90:2160-2164.
20. Schoonjans, K., B. Staels, and J. Auwerx. 1996. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37:907-925.
21. Yu, K., W. Bayona, C.B. Kallen, H.P. Harding, C.P. Ravera, G. McMahon, M. Brown, and M.A. Lazar. 1995. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270:23975-23983.
22. 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell. 83:803-812.
23. Forman, B.M., E. Goode, J. Chen, A.E. Oro, D.J. Bradley. T. Perlmann, D.J. Noonan, L.T. Burka, T. McMorris, W.W. Lamph, et al. 1995. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 81:687-693.
24. Hurt, K., K. Hanley, M.L. Williams, and K.R. Feingold. 1995. Cutaneous lipid synthesis during late fetal development in the rat. Arch. Dermatol. Res. 287:754-760.
25. Feingold, K.R. The regulation and role of epidermal lipid synthesis. Adv. Lipid Res. 24:57-82.
26. Bocos, C., M. Gottlicher, K. Gearing, C. Banner, E. Enmark, M. Teboul, A. Crickmore, and J. Gustafsson. 1995. Fatty acid activation of peroxisome proliferator-activated receptor (PPAR). J. Steroid Biochem. Mol. Biol. 53:467-473.
27. Devchand, P.R., H. Keller, J.M. Peters, M. Vazquez, F.J. Gonzalez, and W. Wahli. 1996. The PPARα-leukotriene B4 pathway to inflammation control. Nature (Lond.). 384:39-43.
28. Goldstein, J.L., and M.S. Brown. 1990. Regulation of the mevalonate pathway. Nature (Lond.). 343:425-430.
29. Holleran, W.M., Y. Takagi, G.M. Menon, G. Legler, K.R. Feingold, and P.M. Elias. 1993. Processing of epidermal glucosylceramides is required for optional mammalian cutaneous permeability barrier function. J. Clin. Invest. 91: 1656-1664.
30. Correll, C.C., L. Ng, and P.A. Edwards. 1994. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 269:17390-17393.
31. Weinberger, C. 1996. A model for farnesoid feedback control in the mevalonate pathway. Trends Endocrinol. Metab. 7:1-6.
32. Voziyan, P.A., C.M. Goldner, and G. Melnykovch. 1993. Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing cholinephosphotransferase activity. Biochem. J. 295:757-762.
33. Haug, J.S., C.M. Goldner, E.M. Yazlovitskaya, P.A. Voziyan, and G.M. Melnykovych. 1994. Directed cell killing (apoptosis) in human lymphoblastoid cells incubated in the presence of farnesol: effect of phosphatidylcholine. Biochim. Biophys. Acta. 1223:133-140.
34. Roullet, J., H. Xue, J. Chapman, P. McDougal, C.M. Roullet, and D.A. McCarron. 1996. Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J. Clin. Invest. 97:2384-2390.
35. Holt, P.J., J. Lazarus, and R. Marks. 1977. The epidermal response to changes in thyroid status. J. Invest. Dermatol. 68:299-301.
36. Fell, H.B., and E. Mellenby. 1953. Metaplasia produced in cultures of chick ectoderm by high vitamin A. J. Physiol. 19:470-488.
37. Elias, P.M., and D.S. Friend. 1976. Vitamin A-induced mucous metaplasia: an in vitro system for modulating tight and gap junction differentiation. J. Cell Biol. 68:173-188.
38. Pillai, S., D.D. Bikle, and P.M. Elias. 1988. Vitamin D and epidermal differentiation: evidence for a role of exogenously produced vitamin D metabolites in keratinocyte differentiation. Skin Pharmacol. 1:149-160.
39. Regnier, M., and M. Darmon. 1991. 1,25-Dihydroxyvitamin D3 stimulates specifically the last steps of epidermal differentiation of cultured human keratinocytes. Differentiation. 47:173-188.
40. Hodson, W.A. 1992. Normal and abnormal structural development of the lung. In Fetal and Neonatal Physiology. R.A. Polin and W.W. Fox, editors. W.B. Saunders Co., Philadelphia. 771-782.
41. Schellhase, D.E., P.A. Emrie, J.H. Fisher, and J.M. Shannon. 1989. Ontogeny of surfactant apoproteins in the rat. Pediatr. Res. 26:167-174.
42. Ballard, P.L. 1989. Hormonal regulation of pulmonary surfactant. Endocrinol. Rev. 10:165-178.
43. Fringes, B., K. Gorgas, and A. Reith. 1988. Clofibrate increases the number of peroxisomes and of lamellar bodies in alveolar cells type II of the rat lung. Eur. J. Cell Biol. 46:136-143.
44. Lemberger, T., B. Staels, R. Saladin, B. Desvergne, J. Auwerx, and W. Wahli. 1994. Regulation of the peroxisome proliferator-activated receptor a gene by glucocorticoids. J. Biol. Chem. 269:24527-24530.
45. Steineger, H.H., H.N. Sorensen, J.D. Tugwood, S. Skerede, O. Spydevoid, and K.M. Gautvik. 1994. Dexamethasone and insulin demonstrate marked and opposite regulation of the steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells. Eur. J. Biochem. 225:967-974.
46. Imamura, T., I. Takata, M. Ogasawara, Y. Matsutani, T. Yamamoto, and C. Asagami. 1991. Clofibrate treatment of psoriasis with hypertriglycemia -clinical, histological and laboratory analysis. Nippon Hifuka Gakkai Zasshi, 101:623-628.